Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials

Dermatology and Therapy

Volumn 6, Issue 1, 2016, Pages 25-37

  Farahnik, Benjamin ^a   Beroukhim, Kourosh ^b   Zhu, Tian Hao ^c   Abrouk, Michael ^d   Nakamura, Mio ^e   Singh, Rasnik ^b   Lee, Kristina ^e   Bhutani, Tina ^e   Koo, John ^e  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti interleukin 17; Biologics; Interleukin 17; Ixekizumab; Phase III; Psoriasis; UNCOVER

Indexed keywords

ETANERCEPT; IXEKIZUMAB; PLACEBO;

CANDIDIASIS; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INJECTION SITE REACTION; MEDLINE; MULTICENTER STUDY (TOPIC); NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SYSTEMATIC REVIEW; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 84961839590     PISSN: 21938210     EISSN: 21909172     Source Type: Journal    
DOI: 10.1007/s13555-016-0102-0     Document Type: Review

References (34)

1. Rachakonda T, Schupp C, Armstrong A. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–6.
2. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871–81 (e1–30).
3. Feldman SR, Malakouti M, Koo JY. Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online J. 2014;20(8).
4. Roark CL, Simonian PL, Fontenot AP, Born WK, O’Brien RL. Gammadelta T cells: an important source of IL-17. Curr Opin Immunol. 2008;20(3):353–7.
5. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821–52.
6. Krueger JG, Fretzin S, Suárez-Fariñas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145–54 (e9).
7. Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 2007;17(5):435–40.
8. Laan M, Cui ZH, Hoshino H, et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol. 1999;162(4):2347–52.
9. Kao CYY, Chen Y, Thai P, et al. IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. J Immunol. 2004;173(5):3482–91.
10. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101(7):2620–7.
11. Ariza MEE, Williams MV, Wong HK. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application. Clin Immunol. 2013;146(2):131–9.
12. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207–11.
13. Yilmaz SB, Cicek N, Coskun M, Yegin O, Alpsoy E. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res. 2012;304(6):465–9.
14. Brown G, Malakouti M, Wang E, Koo J, Levin E. Anti-IL-17 phase II data for psoriasis: a review. J Dermatolog Treat. 2014;26(1):32–6.
15. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130(5):1373–83.
16. Gordon KB. Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 60-week results from a double-blind phase 3 induction and randomized withdrawal study (UNCOVER-1). Presented at: 73rd Annual Meeting of the American Academy of Dermatology; San Francisco; 2015.
17. Griffiths C, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. The Lancet. 2015;386(9993):541–51.
18. Revicki DA, Willian MK, Menter A, Saurat JHH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology (Basel). 2008;216(3):260–70.
19. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65–8.
20. Boisson B, Wang C, Pedergnana V, et al. An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity. 2013;39(4):676–86.
21. Gao S, Huang K, Tu H, Adler A. Monoclonal antibody humanness score and its applications. BMC Biotechnol. 2013;13(1):55.
22. Levin EC, Gupta R, Brown G, Malakouti M, Koo J. Biologic fatigue in psoriasis. J Dermatolog Treat. 2014;25(1):78–82.
23. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010;2(3):256–65.
24. Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol. 2007;25(12):1369–72.
25. Langenbruch A, Radtke MA, Krensel M, Jacobi A, Reich K, Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171(5):1123–8.
26. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med. 2015;373(14):1329–39.
27. Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44(2):183–93.
28. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359(1–2):419–29.
29. Eli Lilly and Company. Lilly’s Ixekizumab met primary endpoint in a phase 3 study investigating the treatment of psoriatic arthritis. http://www.prnewswire.com/news-releases/lillys-ixekizumab-met-primary-endpoint-in-a-phase-3-study-investigating-the-treatment-of-psoriatic-arthritis-300068249.html. PR Newswire, 2015. Accessed 21 Dec 2015.
30. Wu JJ, Poon KYTY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–50.
31. De Boer OJ, van der Meer JJ, Teeling P, et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol. 2010;220(4):499–508.
32. Csiszar A, Ungvari Z. Synergistic effects of vascular IL-17 and TNFalpha may promote coronary artery disease. Med Hypotheses. 2004;63(4):696–8.
33. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis. 2006;17(8):699–706.
34. Gan EY, Chong WSS, Tey HL. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents. BioDrugs. 2013;27(4):359–73.